SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?

Published on Jul 1, 2021in Gender & Development11.361
· DOI :10.1097/01.NPR.0000753832.85114.65
Source
Abstract
ABSTRACT Sodium-glucose cotransporter-2 (SGLT2) inhibitors can decrease risk for heart failure in patients with type 2 diabetes and can decrease risk of major cardiovascular events in patients with heart failure (HF) and diabetes. Specific SGLT2 inhibitors can also decrease major cardiovascular events in patients with HF only.
References26
Newest
#1Jing Luo (University of Pittsburgh)H-Index: 25
#2Robert G. Feldman (University of Pittsburgh)H-Index: 50
Last. Walid F. Gellad (University of Pittsburgh)H-Index: 34
view all 5 authors...
This cross-sectional study assesses drug coverage, formulary restrictions, median retail prices, and annual out-of-pocket costs associated with commonly used insulin products across Medicare Part D plans.
Source
Ty J. Gluckman, MD, FACC, Chair Niti R. Aggarwal, MD, FACC Nicole M. Bhave, MD, FACC Gregory J. Dehmer, MD, MACC Olivia N. Gilbert, MD, MSc, FACC Chayakrit Krittanawong, MD Dharam J. Kumbhani, MD, SM, FACC Andrea L. Price, CPHQ, RCIS, AACC Javier A. Sala-Mercado, MD, PhD David E.
Source
#1Milton Packer (Baylor University Medical Center)H-Index: 116
#2Stefan D Anker (Baylor University Medical Center)H-Index: 1
Last. Martina Brueckmann (Baylor University Medical Center)H-Index: 1
view all 39 authors...
Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More eviden...
Source
#1Ryuhei Sano (JT: Japan Tobacco)H-Index: 6
#2Yuichi Shinozaki (JT: Japan Tobacco)H-Index: 9
Last. Takeshi Ohta (Kyoto University)H-Index: 21
view all 3 authors...
Glucose is the most abundant monosaccharide, and an essential source of energy for most living cells. Glucose transport across the cell membrane is mediated by two types of transporters: facilitative glucose transporters (GLUTs, gene name: solute-carrier (SLC)2A) and sodium glucose co-transporters (SGLTs, gene name: SLC5A). Each transporter has its own substrate specificity, distribution, and regulatory mechanisms. Recently, sodium glucose co-transporter (SGLT)1 and SGLT2 have attracted much att...
Source
#1Maya Guglin (IU: Indiana University)H-Index: 27
#2Mark Zucker (RU: Rutgers University)H-Index: 3
view all 11 authors...
Abstract Timely referrals for transplantation and left ventricular assist device implantation play a key role in favorable outcomes in patients with advanced heart failure. Nonetheless, evaluation usually occurs at advanced heart failure centers and is obscured from referring physicians. The purposes of this review are to explain the decision-making process for candidacy for advanced therapies and to describe the potential impact of the new organ allocation algorithm on center decision making. T...
Source
#1B. Lampert (The Ohio State University Wexner Medical Center)H-Index: 7
#2D.B. DykeH-Index: 15
Last. Todd M. KoellingH-Index: 25
view all 3 authors...
Heart failure is a clinical syndrome in which abnormal cardiac function causes either a failure of the heart to pump blood at a rate matching the requirement of metabolizing tissues, or a situation in which filling pressures are elevated, or frequently both conditions simultaneously. Patients with impaired cardiac pumping function experience symptoms related to abnormal perfusion and retention of vascular fluid volume. The cardinal symptoms of heart failure include fatigue or exercise intoleranc...
Source
Ty J. Gluckman, MD, FACC, Chair Niti R. Aggarwal, MD, FACC Nicole M. Bhave, MD, FACC Gregory J. Dehmer, MD, MACC Olivia N. Gilbert, MD, MSc, FACC Dharam J. Kumbhani, MD, SM, FACC Andrea L. Price, MS, CPHQ, RCIS, AACC David E. Winchester, MD, MS, FACC Martha Gulati, MD, MS, FACC— Ex
Source
#1Carolyn S.P. LamH-Index: 80
Last. Subodh Verma (U of T: University of Toronto)H-Index: 72
view all 4 authors...
Heart failure (HF) is a growing public health issue. As many as 1 in 5 people are expected to develop HF during their lifetime,1 with an estimated 63 million people affected worldwide.2 In 2012 HF was responsible for an estimated health expenditure of $31 billion USD, a figure anticipated to see an increase of 127% by 2030.3 The increasing burden of HF on health care is primarily due to an aging population, as evidenced by the predominance of HF as a cause of hospitalization in individuals aged ...
Source
#1John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
#2Scott D. Solomon (Brigham and Women's Hospital)H-Index: 158
Last. Jan Bělohlávek (Charles University in Prague)H-Index: 12
view all 38 authors...
Abstract Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-ind...
Source
#1Shannon M. DunlayH-Index: 56
#2Michael M. GivertzH-Index: 72
Last. Ileana L. PiñaH-Index: 61
view all 13 authors...
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diab...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.